Analysts had set the expectations bar high, but Genentech Inc. vaulted over it - again - with a second-quarter earnings report showing product sales of $913.4 million, a 42 percent increase over the same period last year, powered largely by sales of the colorectal wonder-drug Avastin. (BioWorld Today)